$3,000.00
PharmaVitae explores Allergan’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.
PharmaVitae explores Allergan’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.
Explore and visualize revenue dynamics in Allergan’s portfolio out to 2027 using 10-year in-house sales forecasts segmented by the following sections.
5 OVERVIEW
5 Snapshot
5 Model updates
5 Analysis structure
7 Q2 2018 REVIEW
7 A strong Q2 for Allergan amid key pipeline wins
10 Q1 2018 REVIEW
10 Allergan records a strong start to 2018 ahead of generic market entries
12 Q4 2017 REVIEW
12 Allergan reports 12% net revenue growth in Q4 2017
17 Q3 2017 REVIEW
17 Allergan reports solid quarter as generic pressures loom in 2018
17 Restasis intellectual property protection
18 Loss of exclusivity in 2018
19 Advancement of six key R&D programs
20 Bibliography
21 STRATEGY ANALYSIS
21 Acquisition trail
21 Growth Pharma
22 Acquisitions and R&D spending
22 Pending loss of exclusivity
23 Investor pressure and decision to sell women’s health and infectious diseases businesses
23 Allergan’s SWOT analysis
24 Allergan’s key events and catalysts
25 Bibliography
27 PORTFOLIO ANALYSIS
31 Q1 2018
34 FACTS AND FIGURES
34 Allergan’s prescription pharma sales outlook
34 Allergan’s regional pharma sales outlook
36 Allergan’s therapy area dynamics
52 Allergan’s portfolio lifecycle analysis
54 Allergan’s pipeline analysis
56 Allergan’s M&A strategy and history
60 Bibliography
LIST OF FIGURES
34 Figure 1: Allergan’s prescription pharmaceutical sales ($m) and growth rate (%), 2014–27
36 Figure 2: Allergan’s therapy area dynamics, 2017–27
52 Figure 3: Allergan’s launch/core/expiry portfolio configuration, 2017–27
54 Figure 4: Allergan’s pipeline overview
LIST OF TABLES
19 Table 1: Allergan’s loss of exclusivity product portfolio
28 Table 2: Allergan’s sales by therapy area ($m), 2017–27
35 Table 3: Allergan’s prescription pharmaceutical sales by region ($m), 2017–27
37 Table 4: Allergan’s sales by therapy area ($m), 2017–27
40 Table 5: Allergan’s other portfolio sales, by product ($m), 2017–27
42 Table 6: Allergan’s central nervous system portfolio sales, by product ($m), 2017–27
45 Table 7: Allergan’s gastroenterology portfolio sales, by product ($m), 2017–27
47 Table 8: Allergan’s ophthalmology portfolio sales, by product ($m), 2017–27
49 Table 9: Allergan’s growth drivers and resistors
53 Table 10: Allergan’s sales by launch, core, and expiry portfolio ($m), 2017–27
55 Table 11: Allergan’s launch portfolio sales, by product ($m), 2017–27
57 Table 12: Allergan’s key merger and acquisition deals, 2006–17
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!